Kodiak Sciences Inc (KOD) Stock Price, Quote & News

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degenerati...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 281 0850

Website: kodiak.com

Address:

1200 Page Mill Road, Palo Alto, United States

buylowandwait Dec. 5 at 11:27 PM

$NVCR $KOD The biggest gain for me this year is KOD, which I bought at 2.8 and it is well above 20. It is 800% gain in a little over a year. As it is not in my top 5 positions, the portofolio impact is relatively small. Looking into 2026, I have AI, BIO, adTech & Fintech, and commodity exposure. Both AI and bio are doing well in 2025, but which stock has the biggest potential gain heading into 2026? Strangely enough, despite huge setback, I am still very hopeful for NVCR to come back in 2026. If the company execute well, and stars line up, we could have 800% gain for NVCR in a couple of years.

1 · Reply

Cutlass Dec. 4 at 7:38 PM

$KOD 22's got gobbled up 🦃

0 · Reply

Cutlass Dec. 4 at 4:37 PM

$KOD Working hard 🤠

0 · Reply

spinusn27 Dec. 4 at 4:33 PM

$KOD

0 · Reply

Stekli27 Dec. 4 at 4:23 PM

$KOD here we go 😈

0 · Reply

John_Smithh Dec. 4 at 11:43 AM

$KOD Exciting months ahead . First Ksi 101 24 weeks data readout in beginning of February , then Tarcocimab phase 3 top line data readout in March . Meanwhile we should get news about raising capital . Buckle up folks and good luck !

0 · Reply

popit Dec. 3 at 9:08 PM

$KOD what was todays livestream results?

0 · Reply

Stekli27 Dec. 3 at 8:38 PM

$KOD I’m scared… I’m scared what kind of fu*king BLOCKBUSTER Kodiak could be in 2026 😳😎 The more I listen to Perloth, the more unreal this whole setup feels. If both 101 and 501 hit… oh boy.

0 · Reply

spinusn27 Dec. 3 at 6:34 PM

$KOD the coil is getting ready for the next step of $25. once it breaks this $23.20 range.

0 · Reply

Stekli27 Dec. 1 at 4:38 PM

$KOD very

2 · Reply

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 12, 2025, 5:48 PM EST - 23 days ago

Kodiak Sciences to Present at Upcoming Investor Conferences

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

Oct 31, 2025, 12:01 PM EDT - 5 weeks ago

The Big 3: GOOGL, KOD, FTK

GOOG GOOGL FTK

Sep 15, 2025, 7:00 AM EDT - 2 months ago

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Sep 2, 2025, 8:00 AM EDT - 3 months ago

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

Aug 27, 2025, 10:40 AM EDT - 3 months ago

Harbour BioMed Reports 2025 Interim Results

Aug 27, 2025, 6:54 AM EDT - 3 months ago

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

Aug 19, 2025, 2:18 PM EDT - 3 months ago

Kodiak Sciences to Present at American Chemical Society Fall 2025

Aug 13, 2025, 4:00 PM EDT - 4 months ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 5 months ago

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Jun 25, 2025, 4:45 PM EDT - 5 months ago

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

May 29, 2025, 9:32 PM EDT - 6 months ago

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 14, 2025, 4:15 PM EDT - 7 months ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 1, 2025, 11:43 PM EDT - 7 months ago

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Mar 27, 2025, 4:01 PM EDT - 9 months ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:39 PM EDT - 9 months ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Feb 23, 2025, 8:08 PM EST - 10 months ago

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Feb 4, 2025, 7:30 AM EST - 10 months ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Jan 7, 2025, 6:00 AM EST - 11 months ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 12:33 PM EST - 1 year ago

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Nov 14, 2024, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 11, 2024, 6:15 AM EST - 1 year ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Oct 14, 2024, 5:35 PM EDT - 1 year ago

Kodiak Sciences to Present at Innovate Retina 2024

Sep 23, 2024, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

May 29, 2024, 4:36 PM EDT - 1 year ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 15, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 13, 2024, 7:32 PM EDT - 1 year ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 2, 2024, 4:30 PM EDT - 1 year ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Mar 28, 2024, 8:57 PM EDT - 1 year ago

Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 6:30 AM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 26, 2024, 6:15 AM EDT - 1 year ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Jan 30, 2024, 6:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 4, 2024, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 6, 2023, 5:00 AM EST - 2 years ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 1, 2023, 11:21 PM EDT - 2 years ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Sep 8, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 7, 2023, 6:00 AM EDT - 2 years ago

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

Jul 24, 2023, 6:38 AM EDT - 2 years ago

Kodiak Sciences scraps development of eye disorder drug

Jul 24, 2023, 6:36 AM EDT - 2 years ago

Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

May 15, 2023, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

Apr 21, 2023, 7:30 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

buylowandwait Dec. 5 at 11:27 PM

1 · Reply

Cutlass Dec. 4 at 7:38 PM

$KOD 22's got gobbled up 🦃

0 · Reply

Cutlass Dec. 4 at 4:37 PM

$KOD Working hard 🤠

0 · Reply

spinusn27 Dec. 4 at 4:33 PM

$KOD

0 · Reply

Stekli27 Dec. 4 at 4:23 PM

$KOD here we go 😈

0 · Reply

John_Smithh Dec. 4 at 11:43 AM

0 · Reply

popit Dec. 3 at 9:08 PM

$KOD what was todays livestream results?

0 · Reply

Stekli27 Dec. 3 at 8:38 PM

0 · Reply

spinusn27 Dec. 3 at 6:34 PM

$KOD the coil is getting ready for the next step of $25. once it breaks this $23.20 range.

0 · Reply

Stekli27 Dec. 1 at 4:38 PM

$KOD very

2 · Reply

Doozio Nov. 29 at 6:11 PM

$KOD from MLYS to BILI’s n they gonna aren’t they? Even da $KODK $BBW 🐒🍌🧠⏰♾️

2 · Reply

Stekli27 Nov. 26 at 4:38 PM

$KOD $NRSN still valid, KOD went from 2 -> 23 since April, nrsn from 0.90 -> ? 😇

0 · Reply

Racsoracso Nov. 26 at 2:00 PM

$OTLK $KOD 24$

0 · Reply

stockman33 Nov. 25 at 9:43 PM

$KOD 30s in my Christmas stocking.

0 · Reply

Alliougana Nov. 25 at 9:28 PM

$KOD why are people like you on here so negatively. These drugs have the ability to change people’s lives not just to make us money.

1 · Reply

Universaal Nov. 25 at 8:40 PM

$KOD once drug fails back to .50 cents

1 · Reply

popit Nov. 25 at 5:46 PM

$KOD im in for 1k shares at $4.X whats the ceiling here. Tempted to take profits but this thing littlerly only stock keeping my portfolio in the green

1 · Reply

Cutlass Nov. 24 at 5:27 PM

$KOD 20's scooped up too - 😃

0 · Reply

Kelly12 Nov. 21 at 5:22 PM

$KOD price target?

1 · Reply

Cutlass Nov. 21 at 4:45 PM

$KOD Perky Pop 😀

2 · Reply

Cutlass Nov. 21 at 3:33 PM

$KOD 19's don't last long at all -

0 · Reply

John_Smithh Nov. 21 at 1:25 PM

$KOD Institutions have been loading the last few months .

0 · Reply

Market Cap	1.31B
Revenue (ttm)	0.00
Net Income (ttm)	-176.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	582,800
Avg Vol	919,962
Day's Range	N/A - N/A
Shares Out	53.05M
Stochastic %K	85%
Beta	2.68
Analysts	Sell
Price Target	$21.29